Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carisbamate Open-Label Extension for Partial Onset Seizures
NCT00991757Phase 3Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Feb 2007
- Primary completion
- Oct 2010
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of carisbamate in focal onset seizure, sponsored by SK Life Science, Inc. Primary endpoint: Worsening of seizures, including rates of status epilepticus at 48 months. Started Feb 2007; status: completed.
02
Drugs
carisbamate
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT00991757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00991757.